

RECEIVED  
CENTRAL FAX CENTER

JAN 07 2009

*Exhibit 1*

*The Claims as of January 7, 2008*

Claim 1 (Withdrawn): A pharmaceutical composition comprising a pharmaceutical carrier and at least one compound in isolated or purified form selected from the group consisting of cobaltocene-octamethyl and stigmastan-3,5,-diene.

Claim 2 (Withdrawn): The pharmaceutical composition of claim 1, wherein the compound is cobaltocene-octamethyl.

Claim 3 (Withdrawn): The pharmaceutical composition of claim 1, wherein the compound is stigmastan-3,5,-diene.

Claim 4 (Withdrawn): The pharmaceutical composition of claim 1, comprising cobaltocene-octamethyl, stigmastan-3,5,-diene, and friedelin.

Claim 5 (Withdrawn): The pharmaceutical composition of claim 1, further comprising at least one compound selected from the group consisting of  $\alpha$ -caryophyllene,  $\beta$ -caryophyllene, caryophyllene oxide, friedelin, cyclododecane, acetic acid, and a terpene.

Claim 6 (Withdrawn): The pharmaceutical composition of claim 2, further comprising a terpene or acetic acid.

Claim 7 (Withdrawn): The pharmaceutical composition of claim 6, wherein said terpene is  $\beta$ -myrcene.

Claim 8 (Withdrawn): The pharmaceutical composition of claim 6, further comprising hexadecanoic acid.

Claim 9 (Withdrawn): A pharmaceutical composition comprising a pharmaceutical carrier and at least one compound selected from the group consisting of galoxolide and benzyl salicylate.

Claim 10 (Withdrawn): The pharmaceutical composition of claim 9, comprising galoxolide and benzyl salicylate.

Claim 11 (Withdrawn): The pharmaceutical composition of claim 9, further comprising at least one compound selected from the group consisting of 3-cyclohexane-1-methanol, camphene, 1,4-cycloprop-azulene, and phytol.

Claim 12 (Withdrawn): The pharmaceutical composition of claim 9, wherein the compound is galoxolide.

10/500,098

Claim 13 (Withdrawn): The pharmaceutical composition of claim 9, wherein the compound is benzyl salicylate.

Claim 14 (Withdrawn): The pharmaceutical composition of claim 9, wherein the compound is  $\alpha$ -pinene.

Claim 15 (Withdrawn): A pharmaceutical composition comprising a pharmaceutical carrier and at least one compound selected from the group consisting of galaxolide, benzyl salicylate, eucalyptol and  $\alpha$ -pinene, wherein the composition has antimycobacterial activity.

Claims 16-25 (Canceled).

Claim 26 (Withdrawn): A method of inhibiting the growth of a mycobacterium, comprising administering a composition comprising a carrier and at least one compound selected from among cobaltocene-octamethyl, stigmastan, 3,5-diene, galaxolide, benzyl salicylate, eucalyptol, and  $\alpha$ -pinene.

Claim 27 (Withdrawn): The method of claim 26, wherein said *M. avium*, *M. bovis*, *M. intracellulare*, *M. kansaii*, *M. leprae*, *M. marinum*, *M. phlie*, *M. scrofulaceum*, *M. smegmatis*, *M. fortuitum*, *M. tuberculosis*, or *M. ulcerans*.

Claim 28 (Withdrawn): The method of claim 26, wherein said mycobacterium is in a mammal and said mammal is a human or a bovine.

Claim 29 (Withdrawn): The method of claim 28, wherein said composition is administered orally.

Claim 30 (Withdrawn): The pharmaceutical composition of claim 15, wherein the compound is eucalyptol.

Claim 31 (Withdrawn): The pharmaceutical composition of claim 15, wherein the compound is  $\alpha$ -pinene.

Claim 32 (Currently amended): A method of preparing ~~and use of~~ a composition having antibacterial ~~antimicrobial~~ activity comprising extracting a material from a *Mammea Americana* plant in an organic solvent, contacting the extracted material with a chromatographic separation system, eluting a fraction comprising stigmastan-3,5,-diene ~~having antimicrobial activity~~ from the chromatographic separation system with a mobile polar phase, and ~~administering~~ assaying the fraction ~~having antimicrobial activity to bacteriato ascertain the fraction has antibacterial activity.~~

Claim 33 (Canceled)

10/500,098

Claim 34 (Withdrawn): The method of claim 32, wherein said plant is *Marchantaceae polymorpha hepatica*.

Claim 35 (Withdrawn): The method of claim 32, wherein said plant is *Callistemon citrinus skeels*.

Claim 36 (Canceled).

Claim 37 (Canceled).

Claim 38 (Canceled).

Claim 39 (Canceled).

Claim 40 (Currently amended): The method of claim ~~[[39]]~~ 32, wherein said ~~composition~~ fraction comprising stigmastan-3,5,-diene further comprises at least one compound selected from the group consisting of friedelin, cyclododecane, and acetic acid.

Claim 41 (Currently amended): The method of claim ~~[[39]]~~ 32, wherein said ~~composition~~ fraction comprising stigmastan-3,5,-diene further comprises friedelin.

Claim 42 (Withdrawn): The method of claim 32, wherein said plant material is from leaves of *Marchantaceae polymorpha* and said composition comprises cobaltocene-octamethyl.

Claim 43 (Withdrawn): The method of claim 42, wherein said composition further comprises at least one compound selected from the group consisting of  $\beta$ -myrceane, acetic acid, and hexadecanoic acid.

Claim 44 (Withdrawn): The method of claim 42, wherein said composition further comprises  $\beta$ -myrceane.

Claim 45 (Withdrawn): The method of claim 32, wherein said plant material is from leaves of *Callistemon citrinus* and said composition comprises at least one compound selected from the group consisting of galoxolide, benzyl salicylate, and  $\alpha$ -pinene.

Claim 46 (Withdrawn): The method of claim 45, wherein said composition further comprises at least one compound selected from the group consisting of eucalyptol, a terpene, 3-cyclohexane-1-methanol, camphene, 1,4-cycloprop-azulene, and phytol.

Claim 47 (Previously presented): The method of claim 32, wherein the organic solvent is methylene chloride.

10/500,098

Claim 34 (Withdrawn): The method of claim 32, wherein said plant is *Marchantaceae polymorpha hepatica*.

Claim 35 (Withdrawn): The method of claim 32, wherein said plant is *Callistemon citrinus skeels*.

Claim 36 (Canceled).

Claim 37 (Canceled).

Claim 38 (Canceled).

Claim 39 (Canceled).

Claim 40 (Currently amended): The method of claim ~~[[39]]~~ 32, wherein said ~~composition~~ fraction comprising stigmastan-3,5,-diene further comprises at least one compound selected from the group consisting of friedelin, cyclododecane, and acetic acid~~[[.]]~~.

Claim 41 (Currently amended): The method of claim ~~[[39]]~~ 32, wherein said ~~composition~~ fraction comprising stigmastan-3,5,-diene further comprises friedelin.

Claim 42 (Withdrawn): The method of claim 32, wherein said plant material is from leaves of *Marchantaceae polymorpha* and said composition comprises cobaltocene-octamethyl.

Claim 43 (Withdrawn): The method of claim 42, wherein said composition further comprises at least one compound selected from the group consisting of  $\beta$ -myrceane, acetic acid, and hexadecanoic acid.

Claim 44 (Withdrawn): The method of claim 42, wherein said composition further comprises  $\beta$ -myrceane.

Claim 45 (Withdrawn): The method of claim 32, wherein said plant material is from leaves of *Callistemon citrinus* and said composition comprises at least one compound selected from the group consisting of galoxolide, benzyl salicylate, and  $\alpha$ -pinene.

Claim 46 (Withdrawn): The method of claim 45, wherein said composition further comprises at least one compound selected from the group consisting of eucalyptol, a terpene, 3-cyclohexane-1-methanol, camphene, 1,4-cycloprop-azulene, and phytol.

Claim 47 (Previously presented): The method of claim 32, wherein the organic solvent is methylene chloride.

10/500,098

Claim 48 (Presently amended): The method of claim 32, wherein the [[the]] bacteria is a mycobacterium.

Claim 49 (Previously presented): The method of claim 48, wherein the mycobacterium is *M. avium*, *M. bovis*, *M. intracellulare*, *M. kansasii*, *M. leprae*, *M. marinum*, *M. phlei*, *M. scrofulaceum*, *M. smegmatis*, *M. fortuitum*, *M. tuberculosis*, or *M. ulcerans*.

Claim 50 (Canceled).

Claim 51 (Canceled).

Claim 52 (Canceled).

Claim 53 (Canceled).

Claim 54 (Canceled).

Claim 55 (Canceled).

Claim 56 (Previously presented): The method of Claim 32, wherein the material is extracted from plant leaves.

Claim 57 (Currently amended): The method of claim 40, wherein said ~~composition~~ fraction comprising stigmastan-3,5,-diene further comprises at least one compound selected from the group consisting of a terpene, a caryophyllene, and cyclododecane.

Claim 58 (Previously presented): The method of Claim 32, wherein the administering of the fraction having antimicrobial activity against microbes, comprises assaying the fraction for activity against *E. coli* or mycobacterium.

Claim 59 (Currently amended): A method of preparing a composition having antimicrobial activity, comprising extracting a material from a *Mammea Americana* plant in an organic solvent, contacting the extracted material with a chromatographic separation system, ~~selecting or having pre-selected a fraction having antimicrobial activity for elution from the chromatographic separation system, and eluting and retaining said a fraction~~ comprising stigmastan-3,5,-diene or cobaltocene octamethyl having antimicrobial activity with a mobile polar phase, and assaying the fraction to ascertain the fraction has antibacterial activity.

Claim 60 (Canceled)

Claim 61 (Canceled)

10/500,098

Claim 62 (currently amended): The method of Claim ~~[[61]]~~ 59, wherein said ~~antimicrobial~~  
antibacterial assay is a mycobacterium based assay.